Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q2 2022 · 10-Q
Revenue$32.65M$32.65M+48.2% vs Q2 2021 Net Income-$68.18M-$68.18MN/M vs Q2 2021 EPS Diluted-$1.58-$1.58N/M vs Q2 2021 Operating Income-$62,533,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$70,986,000N/M Margins · derivedOperating margin-191.5%+45.5 pt vs Q2 2021
Net margin-208.8%+52.8 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 3, 2022 · 34 d after period end